RE: Extavia2 Feb 2021 09:22
Pricing will be based on the value to health providers, insurers, national health services etc, in line with comparable drugs. We will need to provide good value for money.
We are not a big pharma that can afford to do this at cost for the PR value. This is not a side project for SNG. We've put £100M into it in the last 12 months and we would like that back for a start please, along with a fair return for the risk we took.
It is not price that is stopping the drug reaching patients. With approval tomorrow we would sell out all we could make. I will be delighted when we're able to drive availability higher and prices down. It will require more investment, whether by us or others, and for that it will need to produce a return.
That's how this works. We did not raise £100M in charity donations, we got it from investors.
We would not be on Activ2 if the US government did not believe we offered value for money.